Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

The pharmaceutical industry faces an innovation crisis with declining R&D productivity, rising costs, and regulatory challenges impacting drug development.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today the pricing of $400.0 million aggregate ...

The global peptide and anticoagulant drugs market is witnessing significant growth, driven by factors such as the rising prevalence of cardiovascular diseases, technological advancements, and the ...